Toll Free: 1-888-928-9744
Toll Free: 1-888-928-9744
Published: Sep, 2016 | Pages:
82 | Publisher: Global Markets Direct
Industry: Pharmaceuticals & Healthcare | Report Format: Electronic (PDF)
Celiac Disease - Pipeline Review, H2 2016 Summary Global Markets Direct's, 'Celiac Disease - Pipeline Review, H2 2016', provides an overview of the Celiac Disease pipeline landscape. The report provides comprehensive information on the therapeutics under development for Celiac Disease, complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The report also covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases. Additionally, the report provides an overview of key players involved in therapeutic development for Celiac Disease and features dormant and discontinued projects. Global Markets Direct's report features investigational drugs from across globe covering over 20 therapy areas and nearly 3,000 indications. The report is built using data and information sourced from Global Markets Direct's proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Drug profiles featured in the report undergoes periodic review following a stringent set of processes to ensure that all the profiles are updated with the latest set of information. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis. The report helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. Note*: Certain sections in the report may be removed or altered based on the availability and relevance of data. Scope - The report provides a snapshot of the global therapeutic landscape of Celiac Disease - The report reviews pipeline therapeutics for Celiac Disease by companies and universities/research institutes based on information derived from company and industry-specific sources - The report covers pipeline products based on various stages of development ranging from pre-registration till discovery and undisclosed stages - The report features descriptive drug profiles for the pipeline products which includes, product description, descriptive MoA, R&D brief, licensing and collaboration details & other developmental activities - The report reviews key players involved Celiac Disease therapeutics and enlists all their major and minor projects - The report assesses Celiac Disease therapeutics based on drug target, mechanism of action (MoA), route of administration (RoA) and molecule type - The report summarizes all the dormant and discontinued pipeline projects - The report reviews latest news related to pipeline therapeutics for Celiac Disease Reasons To Buy - Gain strategically significant competitor information, analysis, and insights to formulate effective R&D strategies - Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage - Identify and understand important and diverse types of therapeutics under development for Celiac Disease - Identify potential new clients or partners in the target demographic - Develop strategic initiatives by understanding the focus areas of leading companies - Plan mergers and acquisitions effectively by identifying key players and it's most promising pipeline therapeutics - Devise corrective measures for pipeline projects by understanding Celiac Disease pipeline depth and focus of Indication therapeutics - Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope - Modify the therapeutic portfolio by identifying discontinued projects and understanding the factors that drove them from pipeline
Table of Contents
Table of Contents 2 List of Tables 6 List of Figures 7 Introduction 8 Global Markets Direct Report Coverage 8 Celiac Disease Overview 9 Therapeutics Development 10 Pipeline Products for Celiac Disease - Overview 10 Pipeline Products for Celiac Disease - Comparative Analysis 11 Celiac Disease - Therapeutics under Development by Companies 12 Celiac Disease - Therapeutics under Investigation by Universities/Institutes 14 Celiac Disease - Pipeline Products Glance 15 Clinical Stage Products 15 Early Stage Products 16 Celiac Disease - Products under Development by Companies 17 Celiac Disease - Products under Investigation by Universities/Institutes 18 Celiac Disease - Companies Involved in Therapeutics Development 19 Amgen Inc. 19 Amyra Biotech AG 20 Avaxia Biologics, Inc. 21 Calypso Biotech SA 22 enGene, Inc 23 F. Hoffmann-La Roche Ltd. 24 Glenmark Pharmaceuticals Ltd. 25 ImmusanT, Inc. 26 Innovate Biopharmaceuticals, Inc. 27 Intrexon Corporation 28 Sanofi 29 Zedira GmbH 30 Celiac Disease - Therapeutics Assessment 31 Assessment by Monotherapy Products 31 Assessment by Target 32 Assessment by Mechanism of Action 34 Assessment by Route of Administration 36 Assessment by Molecule Type 38 Drug Profiles 40 AMG-714 - Drug Profile 40 Product Description 40 Mechanism Of Action 40 R&D Progress 40 AVX-176 - Drug Profile 42 Product Description 42 Mechanism Of Action 42 R&D Progress 42 Biologic for Celiac Disease - Drug Profile 43 Product Description 43 Mechanism Of Action 43 R&D Progress 43 BNZ-2 - Drug Profile 44 Product Description 44 Mechanism Of Action 44 R&D Progress 44 CALY-002 - Drug Profile 45 Product Description 45 Mechanism Of Action 45 R&D Progress 45 ERW-1041E - Drug Profile 46 Product Description 46 Mechanism Of Action 46 R&D Progress 46 GBR-830 - Drug Profile 47 Product Description 47 Mechanism Of Action 47 R&D Progress 47 larazotide acetate - Drug Profile 48 Product Description 48 Mechanism Of Action 48 R&D Progress 48 latiglutenase - Drug Profile 50 Product Description 50 Mechanism Of Action 50 R&D Progress 50 Monoclonal Antibody to Antagonize IL-2R Beta for Celiac Disease, Central Nervous System and Oncology - Drug Profile 53 Product Description 53 Mechanism Of Action 53 R&D Progress 53 Nexvax-2 - Drug Profile 54 Product Description 54 Mechanism Of Action 54 R&D Progress 54 Nexvax-3 - Drug Profile 57 Product Description 57 Mechanism Of Action 57 R&D Progress 57 Oligonucleotides for Celiac Disease - Drug Profile 58 Product Description 58 Mechanism Of Action 58 R&D Progress 58 Protein for Celiac Disease - Drug Profile 59 Product Description 59 Mechanism Of Action 59 R&D Progress 59 Recombinant Enzymes for Celiac Disease - Drug Profile 60 Product Description 60 Mechanism Of Action 60 R&D Progress 60 Recombinant Protein for Celiac Disease and Type-1 Diabetes - Drug Profile 61 Product Description 61 Mechanism Of Action 61 R&D Progress 61 RG-7625 - Drug Profile 62 Product Description 62 Mechanism Of Action 62 R&D Progress 62 Synthetic Peptides to Inhibit DQ2/DQ8 for Celiac Disease and Type 1 Diabetes - Drug Profile 63 Product Description 63 Mechanism Of Action 63 R&D Progress 63 Vaccine for Celiac Disease - Drug Profile 64 Product Description 64 Mechanism Of Action 64 R&D Progress 64 Vaccine for Celiac Disease - Drug Profile 65 Product Description 65 Mechanism Of Action 65 R&D Progress 65 ZED-1227 - Drug Profile 66 Product Description 66 Mechanism Of Action 66 R&D Progress 66 ZED-754 - Drug Profile 67 Product Description 67 Mechanism Of Action 67 R&D Progress 67 Celiac Disease - Dormant Projects 68 Celiac Disease - Product Development Milestones 69 Featured News & Press Releases 69 May 24, 2016: ImmusanT Reports Nexvax2 Phase 1 Data in Patients with Celiac Disease 69 May 19, 2016: ImmusanT Announces Presentations at Digestive Disease Week 2016 70 May 05, 2016: Celimmune Commences First-Ever Dosing with AMG 714 in Celiac Disease 71 Mar 31, 2016: Celimmune Commences Screening in Phase 2 Clinical Study in Refractory Celiac Disease Type II 72 Sep 23, 2015: Celimmune to Present Overview of Non-Dietary Celiac Disease Therapies in Development at Annual Celiac Support Association Meeting 73 Sep 03, 2015: Glenmark's Novel Monoclonal Antibody GBR 830 to Enter Phase 2 Clinical Studies in Atopic Dermatitis and Celiac Disease in US and Europe 73 Jun 22, 2015: Celimmune to Present Experimental Anti3IL315 Antibody AMG!714 at 16th International Coeliac Disease Symposium 74 Jun 22, 2015: Cour Pharmaceuticals Releases Data on Potential Breakthrough Treatment for Celiac Disease 74 Nov 19, 2014: ImmusanT's Immunotherapy for Celiac Disease, Nexvax2, Selected as One of Informa's Top 10 Autoimmune/Anti-Inflammatory Projects to Watch 75 Jun 12, 2014: Potential New Treatment May Protect Celiac Patients from Gluten-Induced Injury 76 Feb 11, 2014: Alba Therapeutics Announces Positive Results of Phase IIb Trial in Celiac Disease 76 Oct 29, 2013: Alvine Pharmaceuticals Doses First Patient in Phase 2b Trial for ALV003 in Celiac Disease 77 Aug 06, 2013: ImmusanT Initiates Study at Joslin Diabetes Center to Investigate Relationship Between Celiac Disease and Type 1 Diabetes 78 Apr 19, 2013: ImmusanT's Epitope-specific Immunotherapy For Celiac Disease Informs Potential Of Vaccines Against Other Autoimmune Diseases 78 Sep 05, 2012: Alvine Pharma's ALV003 Receives Fast Track Designation From FDA For Treatment Of Celiac Disease 79 Appendix 81 Methodology 81 Coverage 81 Secondary Research 81 Primary Research 81 Expert Panel Validation 81 Contact Us 81 Disclaimer 82
List of Tables
Number of Products under Development for Celiac Disease, H2 2016 10 Number of Products under Development for Celiac Disease - Comparative Analysis, H2 2016 11 Number of Products under Development by Companies, H2 2016 13 Number of Products under Investigation by Universities/Institutes, H2 2016 14 Comparative Analysis by Clinical Stage Development, H2 2016 15 Comparative Analysis by Early Stage Development, H2 2016 16 Products under Development by Companies, H2 2016 17 Products under Investigation by Universities/Institutes, H2 2016 18 Celiac Disease - Pipeline by Amgen Inc., H2 2016 19 Celiac Disease - Pipeline by Amyra Biotech AG, H2 2016 20 Celiac Disease - Pipeline by Avaxia Biologics, Inc., H2 2016 21 Celiac Disease - Pipeline by Calypso Biotech SA, H2 2016 22 Celiac Disease - Pipeline by enGene, Inc, H2 2016 23 Celiac Disease - Pipeline by F. Hoffmann-La Roche Ltd., H2 2016 24 Celiac Disease - Pipeline by Glenmark Pharmaceuticals Ltd., H2 2016 25 Celiac Disease - Pipeline by ImmusanT, Inc., H2 2016 26 Celiac Disease - Pipeline by Innovate Biopharmaceuticals, Inc., H2 2016 27 Celiac Disease - Pipeline by Intrexon Corporation, H2 2016 28 Celiac Disease - Pipeline by Sanofi, H2 2016 29 Celiac Disease - Pipeline by Zedira GmbH, H2 2016 30 Assessment by Monotherapy Products, H2 2016 31 Number of Products by Stage and Target, H2 2016 33 Number of Products by Stage and Mechanism of Action, H2 2016 35 Number of Products by Stage and Route of Administration, H2 2016 37 Number of Products by Stage and Molecule Type, H2 2016 39 Celiac Disease - Dormant Projects, H2 2016 68
Speak to the report author to design an exclusive study to serve your research needs.
Your personal and confidential information is safe and secure.
